Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

BACKGROUND: Osimertinib is selective for both epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI) sensitizing and Thr790Met mutations. While intracranial activity of osimertinib is documented in larger trials, a prospective study focusing exclusively on patients with asymptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Peled, Nir, Kian, Waleed, Inbar, Edna, Goldstein, Iris M, Zemel, Melanie, Rotem, Ofer, Rozenblum, Anna B, Nechushtan, Hovav, Dudnik, Elizabeth, Levin, Daniel, Zer, Alona, Keren-Rosenberg, Shoshana, Yust-Katz, Shlomit, Fuchs, Vered, Remilah, Areen A, Shelef, Ilan, Roisman, Laila C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826702/
https://www.ncbi.nlm.nih.gov/pubmed/35156036
http://dx.doi.org/10.1093/noajnl/vdab188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826702/
https://www.ncbi.nlm.nih.gov/pubmed/35156036
http://dx.doi.org/10.1093/noajnl/vdab188

Ejemplares similares